Learn More
The development of a maturing T-cell-mediated immune response was characterized in Parkinson’s disease subjects receiving recombinant human glial-derived neurotrophic factor (r-metHuGDNF) via(More)
OBJECTIVE To demonstrate pharmacokinetic (PK) similarity of biosimilar candidate ABP 501 relative to adalimumab reference product from the USA and European Union (EU) and evaluate safety,(More)